This study aims to assess whether ertapenem as an empiric treatment of third-generation-cephalosporin resistant Enterobacteriaceae (3GCRE) bacteremia is non-inferior to other carbapenems in term of 30-day mortality.
There are limited data of the efficacy of ertapenem as the empiric treatment of serious invasive infections, such as bloodstream infections (BSIs), that are due to ESBL-producing Enterobacteriaceae. Previous studies of ertapenem were done in small group of patients, in less invasive infection, as a definite 'step-down' therapy, or as compared to other non-carbapenem antibiotics.
Study Type
OBSERVATIONAL
Enrollment
427
Ertapenem injection
Other carbapenems injection
Phramongkutklao Hospital
Bangkok, Thailand
30-day mortality
death from any cause within 30 days after the blood culture with bacteraemia is drawn
Time frame: 30 days
In-hospital mortality
death from any cause within the duration of admission with bacteraemia
Time frame: 90 days
14-day mortality
death from any cause within 14 days after the blood culture with bacteraemia is drawn
Time frame: 14 days
90-day mortality
death from any cause within 90 days after the blood culture with bacteraemia is drawn
Time frame: 90 days
• Length of stay
Duration of admission with bacteraemia
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.